<DOC>
	<DOCNO>NCT01796678</DOCNO>
	<brief_summary>Vaso-occlusion contributes significantly morbidity sickle cell disease ( SCD ) . Vaso-occlusive painful episode ( VOE ) common debilitating , cause majority emergency department visit . Currently effort treat painful episode use non-steroidal pain reliever intravenous narcotic offer symptomatic relief , without target underlie mechanism vaso-occlusion.Investigators find arginine deficiency low NO bioavailability occur painful event SCD . Since arginine obligate substrate NO production , acute deficiency associate VOE , investigator hypothesize arginine supplementation may safe beneficial treatment sickle cell pain .</brief_summary>
	<brief_title>Arginine Therapy Sickle Cell Disease-VOC Clinical Trial</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Established Diagnosis Sickle Cell Disease ( SS , SC , Sbeta thal ) Admitted Hospital pain Pain require hospitalization parenteral narcotic , attributable nonsickle cell cause &gt; 3 year old Hemoglobin less 5gm/dL immediate need red cell transfusion Hepatic Dysfunction : increase SGPT &gt; 2x normal value Renal Dysfunction : increase creatinine &gt; 2x normal value &gt; 1.5 Mental status neurological change Pregnancy &gt; 10 Hospitalizations per year history dependance narcotic Inability take oral medication allergy arginine Inability use PCA device &lt; 3 year age</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>vaso-occlusive pain episode</keyword>
	<keyword>arginine</keyword>
	<keyword>nitric oxide</keyword>
</DOC>